Mahjoubi L, Gazzah A, Besse B, Lacroix L, Soria JC

A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib.

Invest New Drugs 34:397-8 (2016)
DOI:10.1007/s10637-016-0332-0

Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, Akimov M, Bufill JA, Lee C, Jentz D, Hoover R, Ou SH, Salgia R, Brennan T, Chalmers ZR, Jaeger S, Huang A, Elvin JA, Erlich R, Fichtenholtz A, Gowen KA, Greenbowe J, Johnson A, Khaira D, McMahon C, Sanford EM, Roels S, White J, Greshock J, Schlegel R, Lipson D, Yelensky R, Morosini D, Ross JS, Collisson E, Peters M, Stephens PJ, Miller VA

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Cancer Discov 5:850-9 (2015)
DOI:10.1158/2159-8290.CD-15-0285

Li Y, Gao L, Ma D, Qiu T, Li W, Li W, Guo L, Xing P, Liu B, Deng L, Fu J, Li J, Yu Y, Ying J

Identification of MET exon14 skipping by targeted DNA- and RNA-based next-generation sequencing in pulmonary sarcomatoid carcinomas.

Lung Cancer 122:113-119 (2018)
DOI:10.1016/j.lungcan.2018.06.001

Reungwetwattana T, Liang Y, Zhu V, Ou SI

The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.

Lung Cancer 103:27-37 (2017)
DOI:10.1016/j.lungcan.2016.11.011

Pasquini G, Giaccone G

C-MET inhibitors for advanced non-small cell lung cancer.

Expert Opin Investig Drugs 27:363-375 (2018)
DOI:10.1080/13543784.2018.1462336